David Hanley
Corporate Officer/Principal at NUVATION BIO INC.
Net worth: 31 440 $ as of 2024-04-29
David Hanley active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NUVATION BIO INC. | Corporate Officer/Principal | 2021-05-31 | - |
Career history of David Hanley
Former positions of David Hanley
| Companies | Position | Start | End |
|---|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-09-03 | 2021-04-30 |
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 2014-07-31 | 2018-07-31 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 2011-05-31 | 2014-07-31 |
Training of David Hanley
| Virginia Commonwealth University | Undergraduate Degree |
| University of Utah | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 4 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BIOXCEL THERAPEUTICS, INC. | Health Technology |
| NUVATION BIO INC. | Health Technology |
| Private companies | 2 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
- Stock Market
- Insiders
- David Hanley
- Experience
